Autologous Stem Cell Transplant Is a Feasible Treatment For Older Relapsed and Refractory Hodgkin Lymphoma Patients

Hillary Glick(Memorial Sloan Kettering Cancer Center), Matthew J. Matasar(Rutgers, The State University of New Jersey), Craig H. Moskowitz(University of Miami), Craig S. Sauter(Memorial Sloan Kettering Cancer Center), Connie Lee(University of Michigan)

Blood

November 15, 2013

10.1182/blood.v122.21.3408.3408

Cited by 1

Related Papers

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2015|740

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

|The Lancet Oncology|2022|429

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

|Blood|2001|427

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

|Nature Reviews Clinical Oncology|2022|324

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

|Journal of Clinical Oncology|1999|303